The binding of CMTM6 to plasma membrane PD-L1 and recycling endosomes, leading to inhibition of endocytosed PD-L1 degradation, subsequently enhances PD-L1 protein stability and promotes tumor immune escape28, whereas H1A (PD-L1 antibody) abolishes the binding of PD-L1 to CMTM6, resulting in PD-L1 degradation by lysosomes30. The gene discussed is CD274; the disease is neoplasm.